Agomab Starts Phase 1 Clinical Study for AGMB-447 in Healthy Subjects and Patients with Idiopathic Pulmonary Fibrosis

GHENT, Belgium, December 14, 2023--Agomab Therapeutics NV (‘Agomab’) today announced that it has dosed the first subject in a first-in-human Phase 1 clinical study of AGMB-447, an inhaled lung-restricted small molecule inhibitor of ALK5 (TGFβRI or ALK5). The study is evaluating AGMB-447 in healthy subjects and in patients with idiopathic pulmonary fibrosis (IPF).

Related Keywords

Belgium , Gretchen Schweitzer , Tim Knotnerus , Trophic Communications , Agomab Therapeutics , Single Ascending Dose , Multiple Ascending Dose , Chief Development Officer , Idiopathic Pulmonary Fibrosis , Fibrostenosing Crohn , Idiopathic Pulmonary , Transforming Growth Factor , Hepatocyte Growth Factor , Stephanie May , Lung Transplant , Lung Diseases , Business Wire ,